Physician profile
James C Ford
NPI 1609033802
$6,035.45
in general payments reported to CMS, 2019-2025
38 companies · $2,853 in 2025
The $2,853 reported for 2025 was more than what 89% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $220 · 2021: $91.67 · 2022: $799 · 2023: $746 · 2024: $773 · 2025: $2,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080 · Travel and Lodging: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.82 |
| Travel and Lodging | $1,292.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,689.20 | 2023-2025 | 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Genzyme Corporation | $445.41 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.81 | 2019-2024 | Ofev |
| Merck Sharp & Dohme LLC | $316.62 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Janssen Pharmaceuticals, INC | $278.51 | 2019-2024 | Xarelto |
| Baxter Healthcare | $255.94 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abiomed | $247.81 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $203.13 | 2022-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $191.22 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Ucb, INC. | $155.10 | 2019-2024 | Briviact |
| Viatris Specialty LLC | $151.73 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $139.07 | 2020-2023 | Nuzyra |
| Mallinckrodt Enterprises LLC | $131.19 | 2019 | |
| Grifols USA, LLC | $125.02 | 2024-2025 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $121.66 | 2022-2024 | Ultomiris, Soliris |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $121.36 | 2019-2025 | Smartvest |
| Chiesi USA, INC. | $113.55 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $107.75 | 2022-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $104.73 | 2022-2025 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $94.58 | 2021-2023 | |
| Mylan Specialty L.P. | $88.40 | 2022-2024 | Yupelri |
| United Therapeutics Corporation | $87.70 | 2021-2022 | |
| Pfizer INC. | $75.57 | 2021-2025 | |
| Insmed, INC. | $60.33 | 2019-2025 | Arikayce |
| E.R. Squibb & Sons, L.L.C. | $55.24 | 2019-2022 | |
| Verona Pharma, INC. | $44.13 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $41.11 | 2019 | |
| Shionogi INC | $37.28 | 2024 | Fetroja |
| Inogen, INC. | $31.71 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ultragenyx Pharmaceutical INC. | $29.98 | 2023 | |
| Vifor Pharma, INC. | $27.92 | 2024 | Zemaira |
| Mallinckrodt Hospital Products INC. | $24.77 | 2020 | |
| Coaptech, INC. | $24.62 | 2025 | Puma System |
| Novartis Pharmaceuticals Corporation | $19.69 | 2019 | |
| Melinta Therapeutics, LLC | $19.20 | 2022 | |
| La Jolla Pharmaceutical Company | $18.83 | 2024 | Giapreza |
| Abbvie INC. | $16.23 | 2025 | |
| Philips North America LLC | $15.35 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.